Literature DB >> 16278822

Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes.

Marisa Parmo-Cabañas1, Isabel Molina-Ortiz, Salomón Matías-Román, David García-Bernal, Xonia Carvajal-Vergara, Inmaculada Valle, Atanasio Pandiella, Alicia G Arroyo, Joaquin Teixidó.   

Abstract

Malignant plasma cells in multiple myeloma home to the bone marrow (BM), accumulate in different niches and, in late disease, migrate from the BM into blood. These migratory events involve cell trafficking across extracellular matrix (ECM)-rich basement membranes and interstitial tissues. Metalloproteinases (MMP) degrade ECM and facilitate tumour cell invasion. The chemokine CXCL12 is expressed in the BM, and it was previously shown that it triggers myeloma cell migration and activation. In the present work we show that CXCL12 promotes myeloma cell invasion across Matrigel-reconstituted basement membranes and type I collagen gels. MMP-9 activity was required for invasion through Matrigel towards CXCL12, whereas TIMP-1, a MMP-9 inhibitor that we found to be expressed by myeloma and BM stromal cells, impaired the invasion. In addition, we show that the membrane-bound MT1-MMP metalloproteinase is expressed by myeloma cells and contributes to CXCL12-promoted myeloma cell invasion across Matrigel. Increase in MT1-MMP expression, as well as induction of its membrane polarization by CXCL12 in myeloma cells, might represent potential mechanisms contributing to this invasion. CXCL12-promoted invasion across type I collagen involved metalloproteinases different from MT1-MMP. These data indicate that CXCL12 could contribute to myeloma cell trafficking in the BM involving MMP-9 and MT1-MMP activities. Copyright 2005 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16278822     DOI: 10.1002/path.1876

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  18 in total

1.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Authors:  Yazan Alsayed; Hai Ngo; Judith Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; G David Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

2.  Potent anti-aging activity of Aruncus dioicus, a native plant of Ulleung-do, South Korea, in CCD-986sk fibroblasts via suppression of matrix metalloproteinases.

Authors:  Dong-Hee Kim; Yong-Sun Moon; Bong-Jeon An; Jun-Ho Son
Journal:  J Nat Med       Date:  2012-02-17       Impact factor: 2.343

Review 3.  Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.

Authors:  Daniela N Petrusca; Kelvin P Lee; Deborah L Galson
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 4.  Profiling distinct mechanisms of tumour invasion for drug discovery: imaging adhesion, signalling and matrix turnover.

Authors:  Neil O Carragher
Journal:  Clin Exp Metastasis       Date:  2008-10-29       Impact factor: 5.150

5.  Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Authors:  Anurag Purushothaman; Ligong Chen; Yang Yang; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

6.  Extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinases (MMPs) as regulators of tumor-host interaction in a spontaneous metastasis model in rats.

Authors:  Ana Carolina Donadio; María Mónica Remedi; Sebastián Susperreguy; Silvia Frede; Mónica Beatriz Gilardoni; Yi Tang; Claudia Gabriela Pellizas; Li Yan
Journal:  Histochem Cell Biol       Date:  2008-09-04       Impact factor: 4.304

7.  CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

Authors:  Abdel Kareem Azab; Judith M Runnels; Costas Pitsillides; Anne-Sophie Moreau; Feda Azab; Xavier Leleu; Xiaoying Jia; Renee Wright; Beatriz Ospina; Alicia L Carlson; Clemens Alt; Nicholas Burwick; Aldo M Roccaro; Hai T Ngo; Mena Farag; Molly R Melhem; Antonio Sacco; Nikhil C Munshi; Teru Hideshima; Barrett J Rollins; Kenneth C Anderson; Andrew L Kung; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

8.  Cell Trafficking in Multiple Myeloma.

Authors:  Giada Bianchi; Shaji Kumar; Irene M Ghobrial; Aldo M Roccaro
Journal:  Open J Hematol       Date:  2012-02-21

9.  Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.

Authors:  Jing Fu; Shirong Li; Rentian Feng; Huihui Ma; Farideh Sabeh; G David Roodman; Ji Wang; Samuel Robinson; X Edward Guo; Thomas Lund; Daniel Normolle; Markus Y Mapara; Stephen J Weiss; Suzanne Lentzsch
Journal:  J Clin Invest       Date:  2016-04-04       Impact factor: 14.808

10.  Actinidia callosa var. callosa suppresses metastatic potential of human hepatoma cell SK-Hep1 by inhibiting matrix metalloproteinase-2 through PI3K/Akt and MAPK signaling pathways.

Authors:  Jeng-Shyan Deng; Jui-Shu Chang; Jung-Chun Liao; Wei Chao; Ming-Ming Lee; Chien-Hua Cheng; Guan-Jhong Huang
Journal:  Bot Stud       Date:  2018-01-22       Impact factor: 2.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.